
LMDXF
Healthcare · Diagnostics & Research · $246.5M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2023
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2023 | Before the open | -0.14 | -0.15 | -6.0% |
| Aug 24, 2023 | Time not confirmed | -0.13 | -0.16 | -21.2% |
| May 16, 2023 | Time not confirmed | -0.14 | -0.13 | +7.1% |
| Mar 21, 2023 | Time not confirmed | -0.19 | -0.12 | +37.0% |
| Nov 9, 2022 | Time not confirmed | -0.25 | -0.21 | +16.0% |
| Aug 18, 2022 | Time not confirmed | -0.25 | -0.31 | -22.0% |
| May 11, 2022 | Time not confirmed | -0.05 | -0.13 | -139.4% |
| Mar 10, 2022 | Time not confirmed | -0.17 | -0.08 | +52.1% |
| Nov 10, 2021 | Time not confirmed | -0.23 | -0.16 | +30.4% |
| Sep 1, 2021 | Time not confirmed | -0.34 | -0.24 | +30.1% |
| Jun 2, 2021 | Time not confirmed | — | 0.19 | — |
| Jan 15, 2021 | Time not confirmed | — | -0.26 | — |
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious…